Together with computational biology, the development of drugs targeting the SLC13A5 could be accelerated for potential therapeutics of carbohydrate and lipid metabolism disorders like diabetes, non-alcoholic fatty liver and obesity. Here, SLC13A5 is linked to obesity due to melanocortin 4 receptor deficiency.